Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$59.56−1.79 (-2.92%)
Close on Nov 18, 2026Market cap $121.75BP/E 13.2Yield 4.18%
Bristol Myers Squibb pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Bristol Myers Squibb's pe ratio was 13.9× on Nov 11, 2026, against 16.6× a year earlier. Over the last 5 years it ranged from 11.4× to 73.7×, with a median of 18.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 13.9× | −4.4 |
| 2025 | Dec 31, 2025 | 18.2× | +6.8 |
| 2024 | Apr 30, 2024 | 11.4× | −1.6 |
| 2023 | Dec 29, 2023 | 13.0× | −10.4 |
| 2022 | Dec 30, 2022 | 23.4× | −49.0 |
| 2020 | Jul 31, 2020 | 72.4× | +53.8 |
| 2019 | Dec 31, 2019 | 18.6× | −40.5 |
| 2018 | Dec 31, 2018 | 59.1× | +34.9 |
| 2017 | Dec 29, 2017 | 24.1× | −5.1 |
| 2016 | Dec 30, 2016 | 29.2× | −35.7 |
| 2015 | Dec 31, 2015 | 64.9× | +28.7 |
| 2014 | Dec 31, 2014 | 36.2× | +4.4 |
| 2013 | Dec 31, 2013 | 31.8× | +1.9 |
| 2012 | Dec 31, 2012 | 29.9× | +11.6 |
| 2011 | Dec 30, 2011 | 18.3× | – |
See a number that looks wrong?